Acknowledgement
We thank Gayoung Shin, MS for contributing to the selection of the articles.
References
- Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med. 2016;374(5):454-468. https://doi.org/10.1056/NEJMra1503523
- Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010;12(5):245-259. https://doi.org/10.1097/GIM.0b013e3181d38f2f
- Kang E, Seong MW, Park SK, Lee JW, Lee J, Kim LS, et al. The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study. Breast Cancer Res Treat. 2015;151(1):157-168. https://doi.org/10.1007/s10549-015-3377-4
- Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80-87. https://doi.org/10.1093/jnci/djn442
- Padamsee TJ, Wills CE, Yee LD, Paskett ED. Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Res. 2017;19(1):34. https://doi.org/10.1186/s13058-017-0826-5
- Meadows R, Padamsee TJ, Paskett ED. Distinctive psychological and social experiences of women choosing prophylactic oophorectomy for cancer prevention. Health Care Women Int. 2018;39(5):595-616. https://doi.org/10.1080/07399332.2018.1424855
- Howard AF, Balneaves LG, Bottorff JL. Women's decision making about risk-reducing strategies in the context of hereditary breast and ovarian cancer: a systematic review. J Genet Couns. 2009;18(6):578-597. https://doi.org/10.1007/s10897-009-9245-9
- Hickey M, Rio I, Trainer A, Marino JL, Wrede CD, Peate M. What information do healthcare professionals need to inform premenopausal women about risk-reducing salpingo-oophorectomy? Menopause. 2020;27(1):20-25. https://doi.org/10.1097/GME.0000000000001421
- Cherry C, Ropka M, Lyle J, Napolitano L, Daly MB. Understanding the needs of women considering risk-reducing salpingo-oophorectomy. Cancer Nurs. 2013;36(3):E33-E38. https://doi.org/10.1097/NCC.0b013e3182642cb5
- Rosenberg SM, Greaney ML, Patenaude AF, Sepucha KR, Meyer ME, Partridge AH. "I don't want to take chances.": a qualitative exploration of surgical decision making in young breast cancer survivors. Psychooncology. 2018;27(6):1524-1529. https://doi.org/10.1002/pon.4683
- Bradbury AR, Ibe CN, Dignam JJ, Cummings SA, Verp M, White MA, et al. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med. 2008;10(3):161-166. https://doi.org/10.1097/GIM.0b013e318163487d
- Kim D, Kang E, Hwang E, Sun Y, Hwang Y, Yom CK, et al. Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation. Fam Cancer. 2013;12(4):621-628. https://doi.org/10.1007/s10689-013-9625-z
- Singh K, Lester J, Karlan B, Bresee C, Geva T, Gordon O. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. Am J Obstet Gynecol. 2013;208(4):329.e1-329.e3296. https://doi.org/10.1016/j.ajog.2013.01.026
- Kim SI, Lim MC, Lee DO, Kong SY, Seo SS, Kang S, et al. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea. J Cancer Res Clin Oncol. 2016;142(1):333-340. https://doi.org/10.1007/s00432-015-2051-x
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097
- Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013;66(4):408-414. https://doi.org/10.1016/j.jclinepi.2012.09.016
- Conley CC, Agnese DM, Vadaparampil ST, Andersen BL. Factors associated with intentions for breast cancer risk management: does risk group matter? Psychooncology. 2019;28(5):1119-1126. https://doi.org/10.1002/pon.5066
- Manoukian S, Alfieri S, Bianchi E, Peissel B, Azzollini J, Borreani C. Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: are there factors associated with the choice? Psychooncology. 2019;28(9):1871-1878. https://doi.org/10.1002/pon.5166
- Andersen MR, Karlan BY, Drescher CW, Paley P, Hawley S, Palomares M, et al. False-positive screening events and worry influence decisions about surgery among high-risk women. Health Psychol. 2019;38(1):43-52. https://doi.org/10.1037/hea0000647
- Ladd MK, Peshkin BN, Senter L, Baldinger S, Isaacs C, Segal H, et al. Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer. Transl Behav Med. 2020;10(2):337-346. https://doi.org/10.1093/tbm/iby101
- Tong A, Kelly S, Nusbaum R, Graves K, Peshkin BN, Valdimarsdottir HB, et al. Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Psychooncology. 2015;24(1):33-39. https://doi.org/10.1002/pon.3560
- van der Aa JE, Hoogendam JP, Butter ES, Ausems MG, Verheijen RH, Zweemer RP. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy. Fam Cancer. 2015;14(4):539-544. https://doi.org/10.1007/s10689-015-9827-7
- Manchanda R, Burnell M, Abdelraheim A, Johnson M, Sharma A, Benjamin E, et al. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis. BJOG. 2012;119(5):527-536. https://doi.org/10.1111/j.1471-0528.2011.03257.x
- Sidon L, Ingham S, Clancy T, Clayton R, Clarke A, Jones EA, et al. Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. Br J Cancer. 2012;106(4):775-779. https://doi.org/10.1038/bjc.2011.573
- Julian-Reynier C, Mancini J, Mouret-Fourme E, Gauthier-Villars M, Bonadona V, Berthet P, et al. Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations. Eur J Hum Genet. 2011;19(5):500-506. https://doi.org/10.1038/ejhg.2010.241
- Skytte AB, Gerdes AM, Andersen MK, Sunde L, Brondum-Nielsen K, Waldstrom M, et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet. 2010;77(4):342-349. https://doi.org/10.1111/j.1399-0004.2009.01329.x
- Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomarkers. 2009;13(1):51-56. https://doi.org/10.1089/gtmb.2008.0067
- Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, et al. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer. 2007;7(11):875-882. https://doi.org/10.3816/CBC.2007.n.053
- Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Lubsen-Brandsma L, Massuger LF, et al. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. J Clin Oncol. 2007;25(3):301-307. https://doi.org/10.1200/JCO.2006.07.4922
- Kram V, Peretz T, Sagi M. Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing. Fam Cancer. 2006;5(4):327-335. https://doi.org/10.1007/s10689-006-0002-z
- Claes E, Evers-Kiebooms G, Decruyenaere M, Denayer L, Boogaerts A, Philippe K, et al. Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behav Med. 2005;31(3):93-105. https://doi.org/10.3200/BMED.31.3.93-106
- Schwartz MD, Kaufman E, Peshkin BN, Isaacs C, Hughes C, DeMarco T, et al. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol. 2003;21(21):4034-4041. https://doi.org/10.1200/JCO.2003.01.088
- Fang CY, Miller SM, Malick J, Babb J, Hurley KE, Engstrom PF, et al. Psychosocial correlates of intention to undergo prophylactic oophorectomy among women with a family history of ovarian cancer. Prev Med. 2003;37(5):424-431. https://doi.org/10.1016/s0091-7435(03)00163-4
- Hurley KE, Miller SM, Costalas JW, Gillespie D, Daly MB. Anxiety/uncertainty reduction as a motivation for interest in prophylactic oophorectomy in women with a family history of ovarian cancer. J Womens Health Gend Based Med. 2001;10(2):189-199. https://doi.org/10.1089/152460901300039566
- Fry A, Rush R, Busby-Earle C, Cull A. Deciding about prophylactic oophorectomy: what is important to women at increased risk of ovarian cancer? Prev Med. 2001;33(6):578-585. https://doi.org/10.1006/pmed.2001.0924
- Meiser B, Butow P, Barratt A, Friedlander M, Gattas M, Kirk J, et al. Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecol Oncol. 1999;75(1):122-129. https://doi.org/10.1006/gyno.1999.5544
- Glassey R, Ives A, Saunders C, Musiello T. Decision making, psychological wellbeing and psychosocial outcomes for high risk women who choose to undergo bilateral prophylactic mastectomy - a review of the literature. Breast. 2016;28:130-135. https://doi.org/10.1016/j.breast.2016.05.012
- Ager B, Butow P, Jansen J, Phillips KA, Porter D; CPM DA Advisory Group. Contralateral prophylactic mastectomy (CPM): a systematic review of patient reported factors and psychological predictors influencing choice and satisfaction. Breast. 2016;28:107-120. https://doi.org/10.1016/j.breast.2016.04.005
- Sun S, Li ST, Ngeow J. Factors shaping at-risk individuals' decisions to undergo genetic testing for cancer in Asia. Health Soc Care Community. 2020;28(5):1569-1577. https://doi.org/10.1111/hsc.12981
- Haroun I, Graham T, Poll A, Sun P, Hill K, Weitzner E, et al. Reasons for risk-reducing mastectomy versus MRI-screening in a cohort of women at high hereditary risk of breast cancer. Breast. 2011;20(3):254-258. https://doi.org/10.1016/j.breast.2011.01.006